IRIS Accounts Production v26.1.10.61 07430530 Board of Directors 1.12.24 30.11.25 30.11.25 false true false false false true false 24910 514022 24910 37363 501569 24910 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh074305302024-11-30074305302025-11-30074305302024-12-012025-11-30074305302023-11-30074305302023-12-012024-11-30074305302024-11-3007430530ns15:EnglandWales2024-12-012025-11-3007430530ns14:PoundSterling2024-12-012025-11-3007430530ns10:Director12024-12-012025-11-3007430530ns10:PrivateLimitedCompanyLtd2024-12-012025-11-3007430530ns10:SmallEntities2024-12-012025-11-3007430530ns10:AuditExempt-NoAccountantsReport2024-12-012025-11-3007430530ns10:SmallCompaniesRegimeForDirectorsReport2024-12-012025-11-3007430530ns10:SmallCompaniesRegimeForAccounts2024-12-012025-11-3007430530ns10:FullAccounts2024-12-012025-11-300743053012024-12-012025-11-300743053042ns10:Director22024-11-300743053042ns10:Director22024-12-012025-11-300743053042ns10:Director22023-12-012024-11-300743053042ns10:Director22025-11-300743053042ns10:Director22024-11-3007430530ns10:Director22024-12-012025-11-3007430530ns10:CompanySecretary12024-12-012025-11-3007430530ns10:RegisteredOffice2024-12-012025-11-3007430530ns5:CurrentFinancialInstruments2025-11-3007430530ns5:CurrentFinancialInstruments2024-11-3007430530ns5:Non-currentFinancialInstruments2025-11-3007430530ns5:Non-currentFinancialInstruments2024-11-3007430530ns5:ShareCapital2025-11-3007430530ns5:ShareCapital2024-11-3007430530ns5:RetainedEarningsAccumulatedLosses2025-11-3007430530ns5:RetainedEarningsAccumulatedLosses2024-11-3007430530ns5:NetGoodwill2024-12-012025-11-3007430530ns5:IntangibleAssetsOtherThanGoodwill2024-12-012025-11-3007430530ns5:NetGoodwill2024-11-3007430530ns5:NetGoodwill2025-11-3007430530ns5:NetGoodwill2024-11-3007430530ns5:PlantMachinery2024-11-3007430530ns5:PlantMachinery2024-12-012025-11-3007430530ns5:PlantMachinery2025-11-3007430530ns5:PlantMachinery2024-11-3007430530ns5:WithinOneYearns5:CurrentFinancialInstruments2025-11-3007430530ns5:WithinOneYearns5:CurrentFinancialInstruments2024-11-3007430530ns10:Director112024-11-3007430530ns10:Director112023-11-3007430530ns10:Director112024-12-012025-11-3007430530ns10:Director112023-12-012024-11-3007430530ns10:Director112025-11-3007430530ns10:Director112024-11-30
REGISTERED NUMBER: 07430530 (England and Wales)













UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 NOVEMBER 2025

FOR

TFR PHARMA LIMITED

TFR PHARMA LIMITED (REGISTERED NUMBER: 07430530)






CONTENTS OF THE FINANCIAL STATEMENTS
for the Year Ended 30 November 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


TFR PHARMA LIMITED

COMPANY INFORMATION
for the Year Ended 30 November 2025







DIRECTORS: N W Raymond
Mrs M Raymond





SECRETARY:





REGISTERED OFFICE: 1&2 Merlins Court
Winch Lane
Haverfordwest
United Kingdom
Pembrokeshire
SA61 1SB





REGISTERED NUMBER: 07430530 (England and Wales)





ACCOUNTANTS: L M Griffiths & Co Limited
Chartered Certified Accountants
1&2 Merlins Court
Winch Lane
Haverfordwest
Pembrokeshire
SA61 1SB

TFR PHARMA LIMITED (REGISTERED NUMBER: 07430530)

BALANCE SHEET
30 November 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 345,549 483,769
Tangible assets 5 89,606 122,563
435,155 606,332

CURRENT ASSETS
Stocks 131,786 137,023
Debtors 6 1,593,648 1,184,683
Cash at bank 116,884 373,123
1,842,318 1,694,829
CREDITORS
Amounts falling due within one year 7 989,588 1,424,812
NET CURRENT ASSETS 852,730 270,017
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,287,885

876,349

CREDITORS
Amounts falling due after more than one
year

8

(880,109

)

(593,292

)

PROVISIONS FOR LIABILITIES (22,402 ) (30,668 )
NET ASSETS 385,374 252,389

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 385,274 252,289
385,374 252,389

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

TFR PHARMA LIMITED (REGISTERED NUMBER: 07430530)

BALANCE SHEET - continued
30 November 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 25 August 2026 and were signed on its behalf by:





N W Raymond - Director


TFR PHARMA LIMITED (REGISTERED NUMBER: 07430530)

NOTES TO THE FINANCIAL STATEMENTS
for the Year Ended 30 November 2025

1. STATUTORY INFORMATION

Tfr Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 0, is being amortised evenly over its estimated useful life of nil years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

TFR PHARMA LIMITED (REGISTERED NUMBER: 07430530)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 30 November 2025

2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 29 (2024 - 26 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 December 2024
and 30 November 2025 1,341,099
AMORTISATION
At 1 December 2024 857,330
Charge for year 138,220
At 30 November 2025 995,550
NET BOOK VALUE
At 30 November 2025 345,549
At 30 November 2024 483,769

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 December 2024 303,611
Additions 794
At 30 November 2025 304,405
DEPRECIATION
At 1 December 2024 181,048
Charge for year 33,751
At 30 November 2025 214,799
NET BOOK VALUE
At 30 November 2025 89,606
At 30 November 2024 122,563

TFR PHARMA LIMITED (REGISTERED NUMBER: 07430530)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 30 November 2025

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 937,991 995,660
Other debtors 655,657 189,023
1,593,648 1,184,683

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Bank loans and overdrafts 92,858 118,918
Hire purchase contracts 11,998 11,998
Trade creditors 494,859 487,923
Taxation and social security 129,256 110,899
Other creditors 260,617 695,074
989,588 1,424,812

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2025 2024
£    £   
Bank loans 844,115 546,300
Hire purchase contracts 35,994 46,992
880,109 593,292

9. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 30 November 2025 and 30 November 2024:

2025 2024
£    £   
N W Raymond and Mrs M Raymond
Balance outstanding at start of year 24,910 -
Amounts advanced 514,022 24,910
Amounts repaid (37,363 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 501,569 24,910